BACTA-GPT: An AI-Based Bayesian Adaptive Clinical Trial Architect
Authors:
Krishna Padmanabhan,
Danny Baker
Abstract:
Bayesian adaptive clinical trials offer a flexible and efficient alternative to traditional fixed-design trials, but their implementation is often hindered by the complexity of Bayesian computations and the need for advanced statistical programming expertise. The authors introduce a custom fine-tuned LLM designed to assist with this and lower barriers to adoption of Bayesian methods for adaptive c…
▽ More
Bayesian adaptive clinical trials offer a flexible and efficient alternative to traditional fixed-design trials, but their implementation is often hindered by the complexity of Bayesian computations and the need for advanced statistical programming expertise. The authors introduce a custom fine-tuned LLM designed to assist with this and lower barriers to adoption of Bayesian methods for adaptive clinical trials. This paper describes the development and fine-tuning of BACTA-GPT, a Large Language Model (LLM)-based tool designed to assist in the implementation of Bayesian Adaptive Clinical Trials. This engine uses GPT-3.5 as the underlying model and takes in Natural Language input from the Statistician or the Trialist. The fine-tuned model demonstrates a viable proof-of-concept in its objectives. Test case evaluations show that the model is capable of generating a fit-for-purpose Bayesian model for an adaptive trial and evaluate its operating characteristics via simulations using R and JAGS. The integration of AI code generation has significant potential to lower technical barriers for the design and implementation of Bayesian Adaptive trials. But they also require attention to important considerations regarding validation and quality control.
△ Less
Submitted 2 July, 2025;
originally announced July 2025.
Statistical Design and Planning of an Adaptive Trial using Hierarchical Composite Outcomes: A Practical example
Authors:
Krishna Padmanabhan,
Cyrus Mehta
Abstract:
Hierarchical composite endpoints, such as those analyzed using the Finkelstein-Schoenfeld (FS) statistic, are increasingly used in clinical trials for their ability to incorporate clinically prioritized outcomes. However, adaptive design methods for these endpoints remain underdeveloped. This paper presents a practical framework for implementing sample size re-estimation (SSR) in trials using hier…
▽ More
Hierarchical composite endpoints, such as those analyzed using the Finkelstein-Schoenfeld (FS) statistic, are increasingly used in clinical trials for their ability to incorporate clinically prioritized outcomes. However, adaptive design methods for these endpoints remain underdeveloped. This paper presents a practical framework for implementing sample size re-estimation (SSR) in trials using hierarchical composites, motivated by a cardiovascular trial with mortality, hospitalization, and a functional response as prioritized endpoints. We use a two-stage adaptive design with a single interim analysis for illustration. The interim analysis incorporates predictive probabilities to determine whether the trial should stop for futility, continue as planned, or increase the sample size to maintain power. The decision framework is based on predefined zones for predictive probability, with corresponding adjustments to the stage 2 sample size. Simulation studies across various treatment scenarios demonstrate strong type I error control and increased power compared to a fixed design, particularly for treatment effects that are clinically relevant but lower than the alternative hypothesis. We also explore an alternative conditional power approach for SSR, offering further sample size optimization. Our results support the use of SSR with hierarchical composite outcomes using an FS statistic, enhancing trial efficiency.
△ Less
Submitted 20 April, 2025;
originally announced April 2025.
